2-(2,2-Dimethylpropoxy)-2-oxoacetic acid | 143427-11-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(2,2-Dimethylpropoxy)-2-oxoacetic acid
• CAS: 143427-11-6
• 化学式: C₇H₁₂O₄
• 分子量: 160.17
• InChiKey: AGGZTRJAEQHFRC-UHFFFAOYSA-N

物化性质

• 沸点：
  236.7±23.0 °C(Predicted)
• 密度：
  1.126±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(2,2-Dimethylpropoxy)-2-oxoacetic acid 、 1,4-萘醌 在 sodium persulfate 、 silver nitrate 作用下， 以 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 2.0h， 以87%的产率得到2-Neopentyl-1,4-naphthoquinone
  参考文献：
  名称：

  草酸单酯对醌类均裂烷基化和羧化反应的选择性新方法

  摘要：

  草酸单酯被过硫酸盐氧化脱羧生成烷基和烷氧羰基；然后将它们用于醌的选择性取代。

  DOI：

  10.1246/cl.1992.1299

文献信息

• A Novel, Simple and Cheap Source of Alkyl Radicals from Alcohols, Useful for Heteroaromatic Substitution
  作者：Fausta Coppa、Francesca Fontana、Edoardo Lazzarini、Francesco Minisci、Giuseppe Pianese、Lihua Zhao

  DOI：10.1246/cl.1992.1295

  日期：1992.7

  Alkyl radicals were easily produced from secondary or tertiary alcohols in a cheap and simple way by silver-catalyzed decarboxylation of oxalic acid monoesters by S2O8=. They were utilized for the alkylation of heteroaromatic bases in a two-phase system, with high yields and selectivity.

  通过 S2O8= 银催化的草酸单酯脱羧反应，可以很容易地从仲醇或叔醇以廉价和简单的方式制备烷基自由基。它们被用于两相系统中杂芳烃碱的烷基化，具有高产率和选择性。
• Tetrahydroquinoline compounds
  申请人：——

  公开号：US20030216428A1

  公开（公告）日：2003-11-20

  Tetrahydroquinoline compounds of general formula (I) or pharmacologically acceptable salts thereof, which have a specific and strong binding affinity for AR, exhibit AR agonism or antagonism, have therapeutic effects on AR-mediated diseases, particularly by not acting excessively on the prostate as AR agonists, but by showing potent action on skeletal muscle tissue and bone tissue; and pharmaceutical compositions comprising the compounds or the salts as active ingredients: 1

  通式（I）的四氢喹啉化合物或其药理学上可接受的盐具有对AR的特异性和强烈的结合亲和力，表现出AR的激动或拮抗作用，对AR介导的疾病具有治疗效果，特别是对骨骼肌组织和骨组织具有强效作用，但作为AR激动剂不会过度作用于前列腺，以及包含这些化合物或盐作为活性成分的制药组合物。
• TETRAHYDROQUINOLINE COMPOUNDS
  申请人：Kaken Pharmaceutical Co., Ltd.

  公开号：EP1325914A1

  公开（公告）日：2003-07-09

  Tetrahydroquinoline compounds of general formula (I) or pharmacologically acceptable salts thereof, which have a specific and strong binding affinity for AR, exhibit AR agonism or antagonism, have therapeutic effects on AR-mediated diseases, particularly by not acting excessively on the prostate as AR agonists, but by showing potent action on skeletal muscle tissue and bone tissue; and pharmaceutical compositions comprising the compounds or the salts as active ingredients:

  通式(I)的四氢喹啉化合物或其药理学上可接受的盐类，它们与AR具有特异性强的结合亲和力，表现出AR激动或拮抗作用，对AR介导的疾病具有治疗作用，特别是作为AR激动剂不会对前列腺产生过度作用，但对骨骼肌组织和骨组织表现出强效作用；以及包含这些化合物或盐类作为活性成分的药物组合物：
• METHOD FOR PRODUCING OLIGOMER AND/OR MONOMER BY DEGRADING BIODEGRADABLE RESIN
  申请人：Toyo Seikan Kaisha, Ltd.

  公开号：EP2348122A1

  公开（公告）日：2011-07-27

  An object of the present invention is to provide a method for efficiently producing an oligomer or a monomer by degrading a biodegradable resin using an enzyme, so that the oligomer or the monomer can be recovered. The present invention provides a method for producing an oligomer and/or a monomer by degrading a biodegradable resin in a degradation liquid containing a biodegradation enzyme, a buffer agent, an organic solvent, and water. In this method, the SP value of the organic solvent is less than 8.5 or more than 11.5, and the percentage content of the organic solvent (by volume) in the degradation liquid is higher than 1% and lower than 15%. In the method for producing an oligomer or a monomer, the degradation percentage of the biodegradable resin is low, and deposits of aggregates of the oligomer and/or the monomer are few, so that the recovery percentage is high.

  本发明的目的是提供一种方法，通过使用酶降解可生物降解树脂，高效生产低聚物或单体，从而回收低聚物或单体。 本发明提供了一种通过在含有生物降解酶、缓冲剂、有机溶剂和水的降解液中降解可生物降解树脂来生产低聚物和/或单体的方法。在该方法中，有机溶剂的 SP 值小于 8.5 或大于 11.5，降解液中有机溶剂的百分比含量（按体积计）高于 1%，低于 15%。在生产低聚物或单体的方法中，生物降解树脂的降解率低，低聚物和/或单体的聚集沉淀物少，因此回收率高。
• TETRAHYDROQUINOLINE DERIVATIVES
  申请人：KAKEN PHARMACEUTICAL CO., LTD.

  公开号：EP1221439B1

  公开（公告）日：2007-01-03